Podcasts about rcc

Message from Jim Lewis on August 3, 2025

Dr. Corsi talks with Mike McCormick, former stenographer for Joe Biden and author of The Case to Impeach and Imprison Joe Biden, about the Obama/Biden administrations' teaming up with Pope Francis and Cardinal Theodore McCarrick and other elements of the Deep State and Deep Church to promote the woke agenda and to fortify the efforts of the globalist elite. McCormick will discuss this subject in-depth in his next book.Visit The Corsi Nation website: https://www.corsination.comIf you like what we are doing, please support our Sponsors:MyVitalC https://www.thetruthcentral.com/myvitalc-ess60-in-organic-olive-oil/Swiss America: https://www.swissamerica.com/offer/CorsiRMP.phpGet Dr. Corsi's new book, The Assassination of President John F. Kennedy: The Final Analysis: Forensic Analysis of the JFK Autopsy X-Rays Proves Two Headshots from the Right Front and One from the Rear, here: https://www.amazon.com/Assassination-President-John-Kennedy-Headshots/dp/B0CXLN1PX1/ref=sr_1_1?crid=20W8UDU55IGJJ&dib=eyJ2IjoiMSJ9.ymVX8y9V--_ztRoswluApKEN-WlqxoqrowcQP34CE3HdXRudvQJnTLmYKMMfv0gMYwaTTk_Ne3ssid8YroEAFg.e8i1TLonh9QRzDTIJSmDqJHrmMTVKBhCL7iTARroSzQ&dib_tag=se&keywords=jerome+r.+corsi+%2B+jfk&qid=1710126183&sprefix=%2Caps%2C275&sr=8-1Join Dr. Jerome Corsi on Substack: https://jeromecorsiphd.substack.com/Visit The Truth Central website: https://www.thetruthcentral.comGet your FREE copy of Dr. Corsi's new book with Swiss America CEO Dean Heskin, How the Coming Global Crash Will Create a Historic Gold Rush by calling: 800-519-6268Follow Dr. Jerome Corsi on X: @corsijerome1Become a supporter of this podcast: https://www.spreaker.com/podcast/corsi-nation--5810661/support.

Episode 308 hosts Dr Raquel Amado (Dental Surgeon from Kent, UK) and Dr Anoob Pakkar-Hull (Cosmetic Physician from London, UK) In our 'Masterclass Series' we host global experts to teach us about fillers, bio-stimulators, bio-remodellers, polynucleotides, exosomes and other products. (For toxin insights, check out our other mini-series, 'The Tox Talks') In Chapter 7 we discuss various different combination treatments that are commonly used in regenerative aesthetics. Raquel and Anoob discuss their experiences and insights with various treatment modalities and cocktails of microtoxin, the various biostimulators, polynucleotides, PRP and exosomes.  Our conversation also highlights their upcoming RCC meeting that will be held in the Azores. RCC will showcase experts for in-depth lectures and debates about these innovative treatments. The event is non-sponsored and aims to foster open, unbiased discussions and on the efficacy and safety of these advanced regenerative therapies. 00:00 Introduction 01:29 IA Competition Details 02:13 Introducing Dr. Raquel Amado and Dr Anoob Pakkar-Hull 07:07 Microtoxin and Combination Therapies 08:47 Exploring Regenerative Aesthetics 15:04 Microtoxin and NCTF: A Powerful Combination 22:50 Biostimulators and Bio Remodelers 32:26 PRP: Experiences and Insights 36:14 Challenges with PRP Consistency 36:49 Equipment and Variability in PRP 37:46 Historical and Current Uses of PRP 38:18 Combining PRP with Other Treatments 40:19 Introduction to Polynucleotides 40:56 Mechanisms and Benefits of Polynucleotides 43:57 Combining Polynucleotides with Other Treatments 50:27 Exosomes: Sources and Uses 53:18 Patient Communication and Treatment Customization 59:15 Debating the Efficacy of Regenerative Treatments 01:04:15 Future of Regenerative Medicine and Conferences 01:08:02 RCC Conference Overview and Invitation   FIND OUT MORE ABOUT REGENERA COLLECTIVE CONFERENCE & BUY TICKETS - IA LISTENERS GET 15% off BY USING THE CODE IA15! CHECK OUT OUR PATREON & GET A 7 DAYS FREE TRIAL! BROWSE OUR IA OFFERS FOR DISCOUNTS & SPECIALS YOUR A BRAND OR COMPANY & WANT TO WORK WITH US APPLY TO BE A GUEST ON OUR PODCAST CONTACT US  

When is Y90 the right treatment for metastatic disease? Join Drs. Tyler Sandow, Zach Berman and host Kavi Krishnasamy in the conclusion of Dosimetry University where they discuss the complexities of treating different variations of metastatic disease and review how they've approached complicated cases with Y90. --- SYNPOSIS The interventional oncologists first outline the types of metastases that they treat, including colorectal, lung, cholangiocarcinoma, breast, gastric, RCC, and melanoma. The doctors then discuss the potential for Y90 to provide palliative relief by reducing tumor-related pain. The conversation also covers key differences between treating liver-dominant and liver-only disease, along with their algorithm for patients not on systemic chemotherapy.The episode then covers advanced concepts in Y90, such as sub-ablative dosing, the possibility of creating an abscopal effect, and how radiation thresholds change depending on treatment goals. They outline their approach to partition dosimetry, using SPECT/CT to calculate tumor-to-normal ratios, and explain how they modify particle counts and microsphere activity, using flow augmentation based on tumor vascularity. Additional discussion includes the impact of mutation status, prior lines of chemotherapy, and tumor response criteria like RECIST 1.1 and mRECIST. The experts conclude with a case series that illustrates decision-making around when to consider Y90, thermal ablation, TACE, or alternative approaches—even in complex cases like sphincter of Oddi dysfunction. The session underscores the nuanced nature of advanced dosimetric techniques and the evolving landscape of interventional oncology. --- TIMESTAMPS 00:00 - Introduction 01:30 - Types of Metastases Treated with Y9002:50 - Liver-Dominant vs. Liver-Only Disease 07:20 - Sub-Ablative Dosing and the Abscopal Effect09:55 - Tips for Partition Dosimetry 15:30 - Clinical Factors in Treatment Planning23:50 - Choosing Ablation, Resection, or Y90 for mCRC30:27 - Case Series: Colorectal Metastases, Biliary Complications, and more46:00 - Final Thoughts: The Evolving Field --- RESOURCES RECIST 1.1 and mRECIST Criteria:https://pmc.ncbi.nlm.nih.gov/articles/PMC9161105/ COLLISION Trial:https://ascopubs.org/doi/10.1200/JCO.2024.42.17_suppl.LBA3501 BackTable Episode on COLLISION Trial:https://www.youtube.com/watch?v=NQLKcv1BRVM FOXFIRE, SIRFLOX, FOXFIRE-Global:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30457-6/fulltext

Today, we have a guest message from Rick Dickinson, RCC's campus administrator and lead pastor of Refuge Church Malin. This message comes from our evening sessions during our mission trip to Paisley. Enjoy and be challenged by this powerful word! Support the show

Today's episode we will cover 2025 updates for localized renal cell carcinoma (RCC) with Dr. Tom Powles and Dr. Brian Rini from the urologic oncology podcast Uromigos! We will discuss risk factors, the presentation, staging, and treatment options. 

At the 2025 Kidney Cancer Research Summit hosted by KidneyCAN, CancerNetwork® spoke with a variety of leading experts about key developments in the research and management of kidney cancer. Throughout the meeting, presenters shared their findings related to updated clinical trial results, personalized cancer vaccines, potential biomarkers of interest, and other advancements in the field. Thomas Powles, MBBS, MCRP, MD, discussed outcomes from a quality-adjusted survival time without symptoms or toxicity (Q-TWiST) analysis of the phase 3 LITESPARK-005 trial (NCT04195750), in which investigators evaluated treatment with belzutifan (Welireg) vs everolimus (Afinitor) among patients with advanced renal cell carcinoma (RCC). Powles, a professor of genitourinary oncology, lead for Solid Tumor Research, and director of Barts Cancer Institute at St. Bartholomew's Hospital, Queen Mary University of London, stated that these data demonstrate how belzutifan is more active and better tolerated than everolimus in this patient population. David A. Braun, MD, PhD, assistant professor at Yale School of Medicine and member of the Center of Molecular and Cellular Oncology within the Yale Cancer Center, detailed his presentation on a personalized neoantigen cancer vaccine as a treatment for those with RCC. Based on his presentation, Braun highlighted how neoantigen vaccines may effectively yield T-cell responses in patients, illustrating a need for additional, larger studies to elucidate the clinical activity of this modality in an adjuvant setting. Additionally, Wenxin (Vincent) Xu, MD, a medical oncologist at Dana-Farber Cancer Institute and an assistant professor of medicine at Harvard Medical School, spoke about his presentation on how kidney injury molecule-1 (KIM-1) may serve as a prognostic biomarker of response to therapy in patients with RCC. His research posed questions on how KIM-1 can inform the use of adjuvant therapy or specific therapeutic combinations like nivolumab (Opdivo) plus ipilimumab (Yervoy) for this patient population. Eric Jonasch, MD, gave an overview of his presentation focused on the Kidney Cancer Research Consortium, a research partnership spanning 7 institutions dedicated to facilitating mechanistic, hypothesis-testing clinical trials in RCC. Jonasch, a professor in the Department of Genitourinary Medical Oncology of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, described how this collaboration aims to link identifiable biological characteristics of RCC subtypes to specific treatment strategies while developing predictive biomarkers. KidneyCAN is a nonprofit organization with a mission to accelerate cures for kidney cancer through education, advocacy, and research funding. You can learn more about KidneyCAN's work here: https://kidneycan.org/ References 1. Powles T, de Velasco G, Choueiri TK, et al. Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of belzutifan versus everolimus in previously treated advanced renal cell carcinoma (RCC): LITESPARK-005 (LS-005). Presented at the 2025 Kidney Cancer Research Summit; July 17-18, 2025; Boston, MA. Abstract 13. 2. Braun DA. Personalized vaccines in kidney cancer: a journey from concept to clinic. Presented at the 2025 Kidney Cancer Research Summit; July 17-18, 2025; Boston, MA. 3. Xu W. From bench to bedside: advancing KIM-1 as a tool for clinical decision-making. Presented at the 2025 Kidney Cancer Research Summit; July 17-18, 2025; Boston, MA. 4. Jonasch E. Building the infrastructure for discovery: a clinical trial consortium to accelerate kidney cancer research. Presented at the 2025 Kidney Cancer Research Summit; July 17-18, 2025; Boston, MA.

27-07-2025- Rich Towards God- Part 1- Luke 12:13-21- Matt Johnson by RCC

This Sunday, we get to hear from a very good friend of mine, Gentry Morris. Gentry is the Lead Pastor at Reston Community Church in Northern Virginia where he serves the RCC family through preaching, teaching, and helping people find deep hope in the gospel of Jesus. Before coming to RCC, Gentry served as a pastor in Washington state and in church planting ministry in Belfast, Northern Ireland. He also has been involved in worship ministry and writing songs for the local church. Gentry plans to preach from Philippians 1:1-11 on finding joy and contentment in our lives, rooted in the gospel, and extending through us in generosity.  ------------------------------------------- Connect with us on Social Media ⁠Website⁠ | ⁠Instagram⁠⁠⁠⁠ | ⁠Threads⁠ | ⁠Facebook⁠⁠⁠⁠ | ⁠Vimeo⁠------------------------------------------- Download our App⁠Apple App Store⁠ | ⁠Google Play Store⁠

Message from Trace Kendrick on July 27, 2025

Keen observers questioned why Pop Benedict XVI really "stepped down" from his post prematurely to make room for the current Pope Francis (Jorge Mario Bergoglio) in 20113. While Pope Benedict was maligned by the mainstream media Pope Francis was heralded by the same MSM members as an Obama-like rockstar, bringing in a Globalist/Socialist agenda into the Roman Catholic Church. While the truth behind the scenes indicates Francis was installed through manipulation by the Obama/Biden administration while the three re-promoted known pedophile Cardinal Theodore McCarrick to international prominence. Together, they worked hard to advance the Globalist Agenda. Hollywood, however, dutifully attempted to Whitewash the controversial Pope Francis installment as a friendly and amicable transition through the Obama-led Netflix service's movie "The Two Popes."Mike McCormick, author of THE CASE TO IMPEACH AND IMPRISOIN JOE BIDEN, and Biden's former stenographer, got to see some of what really happened up close. Mike joins Dr. Jerome Corsi on The Truth Central to talk about it.Visit Mike McCormick's substack here: https://mmccormick.substack.com/p/the-deep-state-hollywood-evil-behindVisit The Corsi Nation website: https://www.corsination.comIf you like what we are doing, please support our Sponsors:MyVitalC https://www.thetruthcentral.com/myvitalc-ess60-in-organic-olive-oil/Swiss America: https://www.swissamerica.com/offer/CorsiRMP.phpGet Dr. Corsi's new book, The Assassination of President John F. Kennedy: The Final Analysis: Forensic Analysis of the JFK Autopsy X-Rays Proves Two Headshots from the Right Front and One from the Rear, here: https://www.amazon.com/Assassination-President-John-Kennedy-Headshots/dp/B0CXLN1PX1/ref=sr_1_1?crid=20W8UDU55IGJJ&dib=eyJ2IjoiMSJ9.ymVX8y9V--_ztRoswluApKEN-WlqxoqrowcQP34CE3HdXRudvQJnTLmYKMMfv0gMYwaTTk_Ne3ssid8YroEAFg.e8i1TLonh9QRzDTIJSmDqJHrmMTVKBhCL7iTARroSzQ&dib_tag=se&keywords=jerome+r.+corsi+%2B+jfk&qid=1710126183&sprefix=%2Caps%2C275&sr=8-1Join Dr. Jerome Corsi on Substack: https://jeromecorsiphd.substack.com/Visit The Truth Central website: https://www.thetruthcentral.comGet your FREE copy of Dr. Corsi's new book with Swiss America CEO Dean Heskin, How the Coming Global Crash Will Create a Historic Gold Rush by calling: 800-519-6268Follow Dr. Jerome Corsi on X: @corsijerome1Become a supporter of this podcast: https://www.spreaker.com/podcast/corsi-nation--5810661/support.

20-07-2025- The Gospel of Luke- Luke 12:1-12- Mark Koekemoer by RCC

Message from Terry Williams on July 20, 2025

Presentation Life Group Notes DEVOTIONAL Permalink

From game-changing trial results to the evolving science behind personalized cancer care, this week's OncoAlert Round Up dives into the most impactful studies shaking up the oncology landscape. We explore the TALAPRO-2 trial's final analysis showing that talazoparib plus enzalutamide significantly improves survival in men with HRR-deficient mCRPC—especially those with BRCA1/2 alterations—positioning it as a potential new standard of care. Plus, we unpack new insights into geriatric assessment in oncology, breastfeeding post–HR+ breast cancer (POSITIVE trial), non-clear cell RCC, brain metastases at single-cell resolution, MMR-deficient cancer treatment, microbiome modulation, and more. Whether you're a clinician, researcher, or just passionate about cancer science, this episode delivers everything you need to stay ahead.Listen now and subscribe for your weekly dose of cutting-edge cancer care.

Joining the Exchange are Ruth Swain, Director of RCC's SBDC and Tim Busald, SBDC Business Advisor.

Joining the Exchange are Ruth Swain, Director of RCC's SBDC and Tim Busald, SBDC Business Advisor.

Axel Bex joins the show to discuss trials that he thinks have impacted RCC. We also discuss consolidative approaches, neoadjuvant trials and what can impact an academic career.

13-07-2025-Luke 11 vs37-54-Mark Wood by RCC

Message from Terry Williams on July 13, 2025

Video Block Double-click here to add a video by URL or embed code. Learn more Presentation Life Group Notes DEVOTIONAL (TO COME) Permalink

Listen as Michael S. Benninger, MD, describes his approach to the diagnosis and management of chronic cough and refractory chronic cough in the context of a clinically relevant case.PresenterMichael S. Benninger, MDProfessor of Otolaryngology-Head and Neck SurgeryLerner College of MedicineThe Cleveland ClinicPresident, International Association of PhonosurgeryCleveland, OhioLink to full program:https://bit.ly/4kweynG

Message from Terry Williams on July 6, 2025

Message from Trace Kendrick on June 29, 2025

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss important advances in the treatment of prostate, bladder, and kidney cancers that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute and editor-in-chief of the ASCO Daily News.  I am delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of the GU Center at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that were presented at the 2025 ASCO Annual Meeting.  Our full disclosures are available in the transcript of this episode.  Jeanny, it is great to have you on the podcast. Dr. Jeanny Aragon-Ching: Oh, thank you so much, Neeraj. Dr. Neeraj Agarwal: Jeanny, let's begin with some prostate cancer abstracts. Let's begin with Abstract 5017 titled, “Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer.” Can you walk us through the design and the key findings of this first-in-human trial? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this study, presented by Dr. Capucine Baldini, introduces pasritamig, a first-in-class T-cell redirecting bispecific antibody that simultaneously binds KLK2 on prostate cancer cells and CD3 receptor complexes on T cells. KLK2 is also known as human kallikrein 2, which is selectively expressed in prostate tissue. And for reference, KLK3 is what we now know as the PSA, prostate-specific antigen, therefore making it an attractive and specific target for therapeutic engagement. Now, while this was an early, first-in-human, phase 1 study, it enrolled 174 heavily pretreated metastatic CRPC patients. So many were previously treated with ARPIs, taxanes, and radioligand therapy. So given the phase 1 nature of this study, the primary objective was to determine the safety and the RP2D, which is the recommended phase 2 dose. Secondary objectives included preliminary assessment of antitumor activity. So, pasritamig was generally well tolerated. There were no treatment-related deaths. Serious adverse events were rare. And in the RP2D safety cohort, where patients received the step-up dosing up to 300 mg of IV every 6 weeks, the most common treatment-related adverse events were low-grade infusion reactions. There was fatigue and grade 1 cytokine release syndrome, what we call CRS. And no cases of neurotoxicity, or what we call ICANS, the immune effector cell-associated neurotoxicity syndrome, reported. Importantly, the CRS occurred in just about 8.9% of patients. All were grade 1. No patients required tocilizumab or discontinued treatment due to adverse events. So, this suggests a favorable safety profile, allowing hopefully for outpatient administration without hospitalization, which will be very important when we're thinking about bispecifics moving forward. In terms of efficacy, pasritamig showed promising activity. About 42.4% of evaluable patients achieved a PSA50 response. Radiographic PFS was about 6.8 months. And among patients with measurable disease, the objective response rate was about 16.1% in those with lymph node or bone metastases, and about 3.7% in those with visceral disease, with a median duration of response of about 11.3 months. So, altogether, this data suggests that pasritamig may offer a well-tolerated and active new potential option for patients with metastatic CRPC.   Again, as a reminder, with the caveat that this is still an early phase 1 study. Dr. Neeraj Agarwal: Thank you, Jeanny. These are promising results for a bispecific T-cell engager, pasritamig, in prostate cancer. I agree, the safety and durability observed here stand out, and this opens the door for further development, possibly even in earlier disease settings.  So, shifting now from immunotherapy to the evolving role of genomics in prostate cancer. So let's discuss Abstract 5094, a real-world, retrospective analysis exploring the prognostic impact of homologous recombination repair gene mutations, especially BRCA1 and BRCA2 mutations, in metastatic hormone-sensitive prostate cancer. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So this study was presented by Dr. David Olmos, represents one of the largest real-world analyses we have evaluating the impact of homologous recombination repair, or what we would call HRR, alterations in metastatic hormone-sensitive prostate cancer. So, this cohort included 556 men who underwent paired germline and somatic testing. Now, about 30% of patients had HRR alterations, with about 12% harboring BRCA1 or BRCA2 mutations and 16% having alterations in other HRR genes. Importantly, patients were stratified via CHAARTED disease volume, and outcomes were examined across treatment approaches, including ADT alone, doublet therapy, and triplet therapy. The prevalence of BRCA and HRR alterations were about similar between the metastatic hormone-sensitive prostate cancer and the metastatic castrate-resistant prostate cancer, with no differences observed, actually, between the patients with high volume versus low volume disease.  So, the key finding was that BRCA and HRR alterations were associated with poor clinical outcomes in metastatic hormone-sensitive prostate cancer. And notably, the impact of these alterations may actually be even greater in metastatic hormone-sensitive prostate cancer than previously reported in metastatic CRPC. So, the data showed that when BRCA mutations are present, the impact of the volume of disease is actually limited. So, poor outcomes were observed across the board for both high-volume and low-volume groups. So, the analysis showed that patients with HRR alterations had significantly worse outcomes compared to patients without HRR alterations. Median radiographic progression-free survival was about 20.5 months for the HRR-altered patients versus 30.6 months for the non-HRR patients, with a hazard ratio of 1.6. Median overall survival was 39 months for HRR-altered patients compared to 55.7 months for the non-HRR patients, with a hazard ratio of 1.5. Similar significant differences were observed when BRCA-mutant patients were compared with patients harboring non-BRCA HRR mutations. Overall, poor outcomes were independent of treatment of ARPI or taxanes. Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data reinforce homologous recombination repair mutations as both a predictive and prognostic biomarker, not only in the mCRPC, but also in the metastatic hormone-sensitive setting as well. It also makes a strong case for incorporating genomic testing early in the disease course and not waiting until our patients have castration-resistant disease. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. And I think this really brings home the point and the lead up to the AMPLITUDE trial, which is LBA5006, a phase 3 trial that builds on this very concept of testing with a PARP inhibitor, niraparib, in the hormone-sensitive space. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the AMPLITUDE trial, a phase 3 trial presented by Dr. Gerhardt Attard, enrolled 696 patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations. 56% of these patients had BRCA1 and BRCA2 mutations. Patients were randomized to receive abiraterone with or without niraparib, a PARP inhibitor. The majority of patients, 78% of these patients, had high-volume metastatic hormone-sensitive prostate cancer, and 87% of these patients had de novo metastatic HSPC. And 16% of these patients received prior docetaxel, which was allowed in the clinical trial. So, with a median follow-up of nearly 31 months, radiographic progression-free survival was significantly prolonged with the niraparib plus abiraterone combination, and median was not reached in this arm, compared to abiraterone alone, which was 29.5 months, with a hazard ratio of 0.63, translating to a 37% reduction in risk of progression or death. This benefit was even more pronounced in the BRCA1 and BRCA2 subgroup, with a 48% reduction in risk of progression, with a hazard ratio of 0.52. Time to symptomatic progression also improved significantly across all patients, including patients with BRCA1, BRCA2, and HRR mutations. Although overall survival data remain immature, early trends favored the niraparib plus abiraterone combination. The safety profile was consistent with prior PARP inhibitor studies, with grade 3 or higher anemia and hypertension were more common but manageable. Treatment discontinuation due to adverse events remained low at 11%, suggesting that timely dose modifications when our patients experience grade 3 side effects may allow our patients to continue treatment without discontinuation. These findings support niraparib plus abiraterone as a potential new standard of care in our patients with metastatic hormone-sensitive prostate cancer with HRR alterations, and especially in those who had BRCA1 and BRCA2 mutations. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. This trial is especially exciting because it brings PARP inhibitors earlier into the treatment paradigm. Dr. Neeraj Agarwal: Exactly. And it is exciting to see the effect of PARP inhibitors in the earlier setting.  So Jeanny, now let's switch gears a bit to bladder cancer, which also saw several impactful studies. Could you tell us about Abstract 4502, an exploratory analysis from the EV-302 trial, which led to approval of enfortumab vedotin plus pembrolizumab for our patients with newly diagnosed metastatic bladder cancer? So here, the authors looked at the outcomes in patients who achieved a confirmed complete response with EV plus pembrolizumab. Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, EV-302 demonstrated significant improvements in progression-free and overall survival for patients previously treated locally advanced or metastatic urothelial cancer, I'll just call it metastatic UC, as a frontline strategy, establishing EV, which is enfortumab vedotin, plus pembro, with pembrolizumab as standard of care in this setting.  So, this year at ASCO, Dr Shilpa Gupta presented this exploratory responder analysis from the phase 3 EV-302 trial. Among 886 randomized patients, about 30.4% of patients, this is about 133, in the EV+P arm, and 14.5% of the patients in the chemotherapy arm, achieved a confirmed complete response. They call it the CCR rates. So for patients who achieved this, median PFS was not reached with EV+P compared to 26.9 months with chemotherapy, with a hazard ratio of 0.36, translating to a 64% reduction in the risk of progression. Overall survival was also improved. So the median OS was not reached in either arm, but the hazard ratio favored the EV+P at 0.37, translating to a 63% reduction in the risk of death. The median duration of complete response was not reached with EV+P compared to 15.2 months with chemotherapy. And among those patients who had confirmed CRs at 24 months, 78% of patients with the EV+P arm remained progression-free, and around 95% of the patients were alive, compared to 54% of patients who were progression-free and 86% alive of the patients in the chemotherapy arm. Safety among responders were also consistent with prior reports. Grade 3 or higher treatment-related adverse events occurred in 62% of EV+P responders and 72% of chemotherapy responders. Most adverse events were managed with dose modifications, and importantly, no treatment-related deaths were reported among those who were able to achieve complete response.  So these findings further reinforce EV and pembro as the preferred first-line therapy for metastatic urothelial carcinoma, offering a higher likelihood of deep, durable responses with a fairly manageable safety profile. Dr. Neeraj Agarwal: Thank you for the great summary, Jeanny. These findings underscore the depth and durability of responses achievable with this combination and also suggest that achieving a response may be a surrogate for long-term benefit in patients with metastatic urothelial carcinoma.  So now, let's move to Abstract 4503, an exploratory ctDNA analysis from the NIAGARA trial, which evaluated perioperative durvalumab, an immune checkpoint inhibitor, in muscle-invasive bladder cancer. So what can you tell us about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in NIAGARA, presented by Dr. Tom Powles, the addition of perioperative durvalumab to neoadjuvant chemotherapy, gem/cis, significantly improved event-free survival, overall survival, and pathologic complete response in patients with cisplatin-eligible muscle-invasive bladder cancer. Recall that this led to the U.S. FDA approval of this treatment regimen on March 28, 2025.  So, a planned exploratory analysis evaluated the ctDNA dynamics and their association with clinical outcomes, which was the one presented recently at ASCO. So, the study found that the incidence of finding ctDNA positivity in these patients was about 57%. Following neoadjuvant treatment, this dropped to about 22%, with ctDNA clearance being more common in the durvalumab arm, about 41%, compared to the chemotherapy control arm of 31%. Notably, 97% of patients who remained ctDNA positive prior to surgery failed to achieve a pathologic CR. So, this indicates a strong association between ctDNA persistence and lack of tumor eradication. So, postoperatively, only about 9% of patients were ctDNA positive. So, importantly, durvalumab conferred an event-free survival benefit regardless of ctDNA status at both baseline and post-surgery. Among patients who were ctDNA positive at baseline, durvalumab led to a hazard ratio of 0.73 for EFS. So, this translates to a 27% reduction in the risk of disease recurrence, progression, or death compared to the control arm. In the post-surgical ctDNA-positive group, the disease-free survival was also improved with a hazard ratio of 0.49, translating to a 51% reduction in the risk of recurrence.  So, these findings underscore the prognostic value of ctDNA and suggest that durvalumab provides clinical benefit irrespective of molecular residual disease status. So, the data also supports that ctDNA is a promising biomarker for future personalized strategies in the perioperative treatment of muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Thank you, Jeanny. It is great to see that durvalumab is improving outcomes in these patients regardless of ctDNA status. However, based on these data, presence of ctDNA in our patients warrants a closer follow-up with imaging studies, because these patients with positive ctDNA seem to have a higher risk of recurrence. Dr. Jeanny Aragon-Ching: I agree, Neeraj.  Let's round out the bladder cancer discussion with Abstract 4518, which reported the interim results of SURE-02, which is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer. Can you tell us more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure, Jeanny. So, Dr Andrea Necchi presented interim results from the SURE-02 trial. This is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by a response-adapted bladder-sparing treatment and adjuvant pembrolizumab in patients with muscle-invasive bladder cancer.  So, in this interim analysis, 40 patients were treated and 31 patients were evaluable for efficacy. So, the clinical complete response rate was 38.7%. All patients achieving clinical complete response underwent bladder-sparing approach with a repeat TURBT instead of radical cystectomy. Additionally, 51.6% of patients achieved excellent pathologic response with a T stage of 1 or less after neoadjuvant therapy. The treatment was well tolerated, with only 12.9% of patients experiencing grade 3 or higher adverse events without needing dose reduction of sacituzumab. Molecular profiling, interestingly, showed that clinical complete response correlated with luminal and genomically unstable subtypes, while high stromal gene expression was associated with lack of response.  These results suggest that sacituzumab plus pembrolizumab combination has promising activity in this setting, and tolerability, and along with other factors may potentially allow a bladder preservation approach in a substantial number of patients down the line. Dr. Jeanny Aragon-Ching: Yeah, agree with you, Neeraj. And the findings are very provocative and support completing the full trial enrollment and further exploration of this strategy in muscle-invasive bladder cancer in order to improve and provide further bladder-sparing strategies. Dr. Neeraj Agarwal: Agree. So, let's now turn to the kidney cancer, starting with Abstract 4505, the final overall analysis from CheckMate-214 trial, which evaluated nivolumab plus ipilimumab, so dual checkpoint inhibition strategy, versus sunitinib in our patients with metastatic clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So, the final 9-year analysis of the phase 3 CheckMate-214 trial confirms the long-term superiority of nivolumab and ipilimumab over sunitinib for first-line treatment of advanced metastatic renal cell carcinoma. So, this has a median follow-up of 9 years. Overall survival remains significantly improved with the combination. So, in the ITT patient population, the intention-to-treat, the hazard ratio for overall survival was 0.71. So, this translates to a 29% reduction in the risk of death. 31% of patients were alive at this 108-month follow-up compared to 20% only in those who got sunitinib. So, similar benefits were observed in the intermediate- and poor-risk groups with a hazard ratio of 0.69, and 30% versus 19% survival at 108 months.  Importantly, a delayed benefit was also seen in those favorable-risk patients. So, the hazard ratio for overall survival improved from 1.45 in the initial report and now at 0.8 at 9 years follow-up, with 35% of patients alive at 108 months compared to 22% in those who got sunitinib. Progression-free survival also favored the nivo-ipi arm across all risk groups. At 96 months, the probability of remaining progression-free was about 23% compared to 9% in the sunitinib arm in the ITT patient population, 25% versus 9% in the intermediate- and poor-risk patients, and 13% compared to 11% in the favorable-risk patients. Importantly, at 96 months, 48% of patients in the nivo-ipi responders remained in response compared to just 19% in those who got sunitinib. And in the favorable-risk group, 36% of patients who responded remained in response, although data were not available for sunitinib in this subgroup.  So, this data reinforces the use of nivolumab and ipilimumab as a durable and effective first-line effective strategy for standard of care across all risk groups for advanced renal cell carcinoma. Dr. Neeraj Agarwal: Thank you, Jeanny. And of course, since ipi-nivo data were presented, several other novel ICI-TKI combinations have emerged. And I'm really hoping to see very similar data with TKI-ICI combinations down the line. It is really important to note that we are not seeing any new safety signals with the ICI combinations or ICI-based therapies, which is very reassuring given the extended exposure. Dr. Jeanny Aragon-Ching: Absolutely agree with you there, Neeraj.  Now, going on and moving on to Abstract 4514, which is the KEYNOTE-564 trial, and they reported on the 5-year outcomes of adjuvant pembrolizumab in clear cell RCC in patients who are at high risk for recurrence. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the KEYNOTE-564 trial established pembrolizumab monotherapy as the first adjuvant regimen to significantly improve both disease-free survival and overall survival compared to placebo after surgery for patients with clear cell renal cell carcinoma. So, Dr Naomi Haas presented the 5-year update from this landmark trial.  A total of 994 patients were randomized to receive either pembrolizumab or placebo. The median follow-up at the time of this analysis was approximately 70 months. Disease-free survival remained significantly improved with pembrolizumab. The median DFS was not reached with pembrolizumab compared to 68.3 months with placebo, with a hazard ratio of 0.71, translating to a 29% reduction in risk of recurrence. At 5 years, 60.9% of patients receiving pembrolizumab remained disease-free compared to 52.2% with placebo. Overall survival also favored pembrolizumab. The hazard ratio for OS was 0.66, translating to a 34% reduction in risk of death, with an estimated 5-year overall survival rate of 87.7% with pembrolizumab compared to 82.3% for placebo. Importantly, these benefits were consistent across all key subgroups, including patients with sarcomatoid features. In addition, no new serious treatment-related adverse events have been reported in the 3 years since treatment completion.  So, these long-term data confirm pembrolizumab as a durable and effective standard adjuvant therapy for patients with resected, high-risk clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Thank you for that wonderful summary, Neeraj. Dr. Neeraj Agarwal: That wraps up our kidney cancer highlights. Any closing thoughts, Jeanny, before we conclude? Dr. Jeanny Aragon-Ching: It's been so wonderful reviewing these abstracts with you, Neeraj. So, the 2025 ASCO Annual Meeting showcased a lot of transformative data across GU cancers, from first-in-class bispecifics to long-term survival in RCC. And these findings are already shaping our clinical practices. Dr. Neeraj Agarwal: I agree. And we have covered a broad spectrum of innovations in GU cancers with strong clinical relevance.  So, thank you, Jeanny, for joining me today and sharing your insights.  And thank you to our listeners for joining us. You will find links to the abstracts discussed today in the transcript of this episode. If you find these conversations valuable, please take a moment to rate, review, and subscribe to the ASCO Daily News Podcast wherever you listen. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Neeraj Agarwal     @neerajaiims     Dr. Jeanny Aragon-Ching   Follow ASCO on social media:       @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn       Disclosures:   Dr. Neeraj Agarwal:   Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences  Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas  Dr. Jeanny Aragon-Ching:   Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono   Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis,    Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics

In honor of The Collective's grand opening, we brought in certified peer specialist John Singer to provide insight into his motivation for creating a recovery community center in Jefferson County. He explains the ability of RCC's to lower barriers to recovery, our partnership with Jefferson Franklin Community Action Corporation, and why transportation services to treatment are so important in JeffCo. Come visit us at The Collective now!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this JCO Precision Oncology Article Insights episode, Natalie DelRocco summarizes "Real-Time Monitoring in Renal Cell Carcinoma With Circulating Tumor DNA: A Step Forward, but How Far?" by Zeynep B. Zengin et al. published on February 28, 2025. TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Natalie DelRocco: Hello, and welcome to JCO Precision Oncology Article Insights. I'm your host, Natalie DelRocco, and today we will be discussing the editorial, "Real-Time Monitoring in Renal Cell Carcinoma With Circulating Tumor DNA: A Step Forward, but How Far?" This editorial by Zengin and Kotecha discusses the impact of circulating tumor DNA (ctDNA) and its potential applications in renal cell carcinoma - we'll call this RCC for the remainder of the podcast. This article was published in February of 2025, and I think this is really timely because ctDNA is currently an emerging biomarker of interest in many different cancers. Having shown promise in certain cancers, other types of cancers are really targeting ctDNA to see if it can be used as a prognostic or a predictive biomarker in their specific field of oncology. Sometimes it is found that ctDNA is a prognostic marker that's associated with outcome, but it's not always clear whether it is a predictive biomarker that can help modify treatment and to what extent it could be helpful modifying treatment. This is what the authors of this editorial really focus on. They focus on the applications of ctDNA in RCC by interpreting the accompanying article, "Longitudinal Testing of Circulating Tumor DNA in Patients With Metastatic Renal Cell Carcinoma" by Basu et al. So, the editorial authors begin by giving examples of cancers where ctDNA has been shown to be useful in cancer monitoring - for example, locally advanced urothelial carcinoma - and they give examples of when it has not been shown to be useful in monitoring colorectal cancer. And this just highlights the variability of ctDNA as a biomarker. It's not always a useful biomarker, but sometimes it is. The authors note that RCC may fall into the latter category - that is, the "not useful" category - due to the low ctDNA shedding which characterizes RCC. However, metastatic RCC - we'll call this ‘mRCC' for the remainder of the podcast - may be a target for use of ctDNA clinically due to advanced assay development, according to the authors. Basu et al, in the original work that the editorial accompanies, showed in a retrospective study of 92 patients with mRCC that ctDNA detectability was associated with poorer PFS, regardless of receipt of active treatment versus no receipt of active treatment. That's important because ctDNA can be directly affected by therapy. The authors of the editorial believe that this is a particularly promising result for a few reasons. Firstly, the estimated hazard ratios were quite large. A hazard ratio of 3.2 was seen in the active treatment group versus a hazard ratio of 18 was observed in the no-active-treatment group. I will note that a hazard ratio of 18 with an extremely wide confidence interval is an unusual observation. So, when interpreting this result, I would consider the direction and magnitude of the effect to be suggestive of promise but needing to be validated in the future to improve precision. And the authors of the editorial do agree with this; they note the same. The authors also note that a single-patient example was used to show how that ctDNA positivity can be used in mRCC to monitor and prompt imaging if disease progression is suspected. And then that way, disease progression can be caught earlier. That to say, there is a real target for clinical use, which isn't always the case. Sometimes we know that ctDNA is associated with outcome, but we don't quite know how we can modify when we know that ctDNA is positive. In this case, the editorial authors show that we can use ctDNA positivity to monitor patients for disease progression. Despite the promise of the study, the editorial does highlight that the study inherits typical retrospective study limitations. For example, there is a heterogeneous cohort. There is variability in data collection, particularly nailing down specific time points, which can always be a challenge when collecting biological samples as part of a study. And small sample size - although 92 patients is great for renal cell carcinoma, it is a challenging sample size with respect to precision of those hazard ratio estimates, which we've already talked about. The authors additionally note that ctDNA could be used to direct therapy, not just to monitor for disease progression. So, both monitoring and changing therapy would certainly require further study and validation, which is discussed by the authors of this editorial. We would want larger, prospective studies showing the same association before we would be comfortable modifying treatment for patients based on their ctDNA positivity level. Thank you for listening to JCO Precision Oncology Article Insights. Don't forget to give us a rating or a review, and be sure to subscribe so that you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Message from Trace Kendrick on June 22, 2025

Message from Jim Lewis on June 15, 2025

Join us this week as we wrap up our latest series, week 8 of "Living With the End in Mind". Not only is our series ending, but today is the day we say goodbye to Pastor Nathan and family as they continue to diligently follow God's direction for their lives. May God continue to bless the Pelehowskis AND Revolution Community Church as their paths part towards the future that God has laid out before them. The Pelehowskis are moving, but the positive impact they're leaving behind will forever leave RCC changed for the better. Remember, YOU matter because GOD SAYS you matter.Visit us at revolutioncc.org

June 8, 2025 | Pastor Richard Pope continues the "Friends of RCC" Gospel Partners' sermon series

Episode 2 - The Emotional Highs & Lows of IVFIn this second episode of our series on IVF, co-host Jill Van Gyn explores the emotional complexities of fertility treatments, with a special focus on IVF and pregnancy loss. Joining her is Alexandra Stewart M.A., RCC, PMH-C, a seasoned fertility therapist with personal and deep expertise in reproductive mental health.They unpack the often unspoken psychological toll of infertility, highlighting:the emotional resilience required to endure repeated treatmentsthe grief of pregnancy lossthe impact of societal and self-imposed expectations on the journey to parenthoodthe unexpected toll it can take on relationships and partnershipsAlexandra shares invaluable insights on the importance of therapy as both a coping mechanism and a community-building tool. She also offers guidance on how to support oneself or a loved one through the profound ups and downs of reproductive challenges.Whether you're facing fertility challenges yourself or supporting someone who is, this conversation offers empathy, understanding, and hope.Trigger Warning: This episode includes sensitive discussions about pregnancy loss.Get 25% off all courses through the end of June 2025! Purchase a Feisty On-Demand Course: learning.feisty.co Sign up to Receive The Feisty 40+ Newsletter:https://www.feistymenopause.com/blog/Feisty-40-plus Sign up to Receive The Feist Newsletter:https://www.womensperformance.com/the-feist Follow us on Instagram:@feisty_womens_performance Feisty Media Website:https://livefeisty.com/ https://www.womensperformance.com/ Support our Partners:Previnex: Get 15% off your first order with the code PERFORMANCE at https://www.previnex.com/

This week's episode will be focusing on exciting data in GU presented at the 2025 ASCO Annual Meeting in prostate (including prognostication of PSA response in mCSPC, AMPLITUDE - PARPi in mCSPC), RCC (including updates in KN-564, CM-214 and PDIGREE), and finally bladder CA (with updates in NIAGARA and EV-302) among others. 

Message from Terry Williams on June 8, 2025

In this powerful message, Pastor Connor unpacks what happens when the anxiety of life collides with the unshakable sovereignty of God. Drawing from Matthew 6:25–33, we're reminded that God sees, knows, and provides for every detail of our lives — from the birds of the air to the lilies of the field, and especially for you.When worry creeps in, Jesus calls us to trust in the Father's care and to seek first His Kingdom. Discover the peace that comes from letting go of control and holding tight to His promises.

June 1, 2025 | Dr. Anush A. John continues the "Friends of RCC" Gospel Partners' sermon series

Message from Aaron Lewis on June 1, 2025

David McDermott joins us on the heels of his outstanding discussion of the clinical science symposium on RCC biomarkers.

Whew, the timeline is HOT and we got a lot to unpack! This week we're back in the mix with a heavy pour of tea, updates, and that signature RCC vibes .  

This Memorial Day, we honor fallen heroes—and the greatest sacrifice of all: Jesus Christ. In this powerful message, Pastor Richard Crisco reminds us that true freedom isn't just national—it's eternal.

Listen as Michael S. Blaiss, MD provides case-based perspectives on chronic cough recognition, burden, management, and pathophysiology and describes the evolving treatment landscape for refractory chronic cough.PresenterMichael S. Blaiss, MDClinical Professor of PediatricsDivision of Allergy-ImmunologyMedical College of Georgia at Augusta UniversityAugusta, GeorgiaLink to full program: https://bit.ly/4kweynG

May 25, 2025 | Pastor in training Brandon Sams continues the sermon, "Friends of RCC"

Message from Aaron Lewis on May 25, 2025

Message from Terry Williams on May 18, 2025

This Mother's Day, Shane Willard brings a powerful message on Pentecost—not just a moment in history, but the beginning of something new: God's Spirit dwelling in people, not buildings.Through Acts 2 and rich Old Testament imagery, we see that God's presence now lives in us. The wind, fire, and voices mark a new kind of temple—a community of love, peace, and blessing for all people, everywhere.

As Shane Willard continues his on the kingdom of God he explores what it means to repent, and how we can see the Kingdom of our life as seed and how we can cultivate it to bear fruit.#ShaneWillard #KingdomOfGodFor more info on RCC visit us at https://rcc4me.comYou can download the sermon notes at https://bit.ly/rccsundays

We're thrilled to welcome Shane Willard as he kicks off a powerful new series exploring what the Kingdom of God truly looks like.In this opening message, Shane challenges a common mindset: that righteousness comes from what we avoid. But Jesus taught something deeper—righteousness isn't found in what we abstain from, but in how we live generously toward others.This teaching will shift your perspective and invite you to embrace a Kingdom that's marked not by rules, but by radical generosity, compassion, and transformation.

Message from Terry Williams on May 11, 2025

Have you ever noticed how our past failures can cloud our future hopes? How the places where we fell short seem to follow us—coloring our perspective, fueling our fears, and shaping how we think about what's ahead?In this powerful message, we dive into John 21, where Peter, once again, finds himself around a fire—fishing, failing, and facing a familiar scene. But this time, Jesus is waiting. The same setting where Peter denied Jesus becomes the setting where he's restored.This sermon reminds us that our greatest moments of shame don't have to define our destiny. Jesus meets us in the very places we feel disqualified and rewrites the story.Don't let the past write the final chapter—God still has more for you.#Sermon #John21 #Peter #Restoration #Faith #Hope #ChristianSermon #OvercomingFailure #JesusRestoresFor more info on RCC visit us at https://rcc4me.comYou can download the sermon notes at https://bit.ly/rccsundays

Patrick examines the influence of Islam in Europe and shares the story of a father's fight for parental rights in the school system. Additionally, he explains theological truths about Jesus's divinity and discusses the concept of Jews as the chosen people. FBI Former FBI agent @JGuandolo54271 discusses what’s actually happening with radical Islam (02:40) Dad OBLITERATES @JeffcoSchoolsCo after they fed his daughter lies about him, alienated her, and undermined his parental rights (08:44) Todd (email) – Why does the RCC’s assertion that Jesus is God. It seems to me, that Jesus, if we believe the Gospels are 100% accurate historical records, went out of his way to ensure nobody mistook him for God by repeatedly referring to himself as Rather the Son of God. It seems also, that Paul’s letters support the assertion that Jesus did not presume or declare that he was God. Why then, did the RCC decide to treat him so? (13:45) Kathy - I feel like the Church is being manipulated into spreading the Islam faith. (25:08) Email – I’m a little anxious about the upcoming Walk to Mary (35:36) Anthony (email) - Please clarify the statement about the Jews being the "Chosen People". Did this end after Jesus' crucifixion or is it still true today? Recently we have seen much antisemitism in our country. I also saw a clip today from Jerusalem where Christians were carrying a cross to reenact the passion of Christ and Jewish youth were spitting at them and telling them to go home and that they were evil. (41:07)